TS23
Phase 2Small molecule
TS23 is one of 60 small molecule programs targeting Pulmonary Embolism. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
116 competitors in Ischemic Stroke
#DrugCompanyPhaseTrials
1Ozempic
Novo NordiskPhase 3
Reminyl
WWim Janssens
Phase 3
Atorvastatin Calcium
Merck & Co.Phase 3
PCSK9 Inhibitor
YYun Dai Chen
Phase 3
Aggrastat
MMedicure
Phase 3
Proamatine
TakedaPreclinical
Levaquin
WWim Janssens
Preclinical
TS23
TTranslational Sciences, Inc.
Phase 2
Tylenol
KKenvue Brands
Preclinical
Xylocaine
CCitius Pharmaceuticals, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TS23. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TTranslational Sciences, Inc.